Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SIROLIMUS
- Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Single Centre, Randomised, Placebo-controlled Trial
- Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
- Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
- Advancing Transplantation Outcomes in Children
- LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
- Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
- Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)
- Allo HSCT Using RIC and PTCy for Hematological Diseases
- A Phase 2a Study of LAM-001 for the Treatment of PH
- Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA
- Study of Sirolimus in IgG4-related Disease
- REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. The RESUS Proof of Concept Study
- Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
- A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)
- Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome
- Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
- Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)
- Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
- A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
- A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
- Sirolimus in Cutaneous Sarcoidosis
- Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blo
- Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
- A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
- Impacts of Mechanistic Target of Rapamycin (mTOR) Inhibition on Aged Human Muscle (Rapamune)
- Short Term Sirolimus Treatment and MRI of the Brain
- TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
- Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
- Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
- Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma
- Sirolimus for Nosebleeds in HHT
- The Role of Sirolimus in Preventing Functional Decline in Older Adults
- Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
- Effect of Loratadine in Lymphangioleiomyomatosis
- Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD
- Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
- A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors
- PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation
- Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1)
- Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4
- Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
- DES and Medical Treatment for ICAD Trial
- Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
- Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
- Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant
- Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies
- CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
- Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
- Methods of T Cell Depletion Trial (MoTD)
- Weekly Sirolimus Therapy
- Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™
- Omega-3 Oil Use in COVID-19 Patients in Qatar
- A Study to Induce Tolerance in de Novo Renal Transplantation
- Phase III Trial of Sirolimus in IBM
- Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
- Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
- Sirolimus Treatment Of Patients With SLE
- Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
- Sirolimus for Retinal Astrocytic Hamartoma
- Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.
- PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
- Sirolimus for Graves' Orbitopathy (GO)
- Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
- Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
- 3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
- The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient
- Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
- Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
- Haplo Peripheral Blood Sct In GVHD Prevention
- Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA
- Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
- Efficacy and Safety of Sirolimus in COVID-19 Infection
- Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
- Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)
- Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
- SCMC Trial on KHE With KMP (V.2020)
- Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
- Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)
- Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy
- Glutamine PET Imaging in LAM
- Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients
- Sirolimus in COVID-19 Phase 1
- Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
- Reduced Intensity Transplantation for Severe Sickle Cell Disease
- Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
- Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
- Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)
- Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
- Immune Monitoring to Facilitate Belatacept Monotherapy
- Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
- Enhancing Self Regulation Among Smokers
- Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
- Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
- TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN
- Phase 1/2a Clinical Trial of PR001 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- Liposomal Sirolimus in Dry Eye Disease
- Sirolimus for Cowden Syndrome With Colon Polyposis
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
- Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
- Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
- Azithromycin a Treatment for Pulmonary Sarcoidosis
- CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction
- Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life
- Optimizing PTCy Dose and Timing
- Topical Sirolimus in Cutaneous Lymphatic Malformations
- NPC-12G Gel 0.2% Sirolimus PK Bridging Study
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type II GM1 Gangliosidosis
- The Efficacy and Safety of Sirolimus for Plastic Bronchitis
- Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
- Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients
- Umbilical Cord Blood Transfusion in Progeria Syndrome
- Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH
- Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
- Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome
- SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients
- Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation
- Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets
- ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
- Altering Memories That Increase Risk of Relapse in Alcohol Use Disorders
- LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
- Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
- Study of Sirolimus in CTD-TP in China
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Trial of eRapa in Prostate Cancer Patients
- CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
- A Futility Trial of Sirolimus in Multiple System Atrophy
- Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease
- Efficacy and Safety of Sirolimus to Vascular Anomalies
- Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation
- Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
- A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer
- Tolerance by Engaging Antigen During Cellular Homeostasis
- Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation
- Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis
- Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation
- Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
- Stem Cell Transplant in Patients With Severe Sickle Cell Disease
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
- Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
- A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis
- Sirolimus Treatment for Refractory PRCA
- Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
- Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
- Rapamycin Treatment for ALS
- Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
- Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
- Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
- Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
- Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy
- Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
- Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure
- Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
- Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
- LAM Pilot Study With Imatinib Mesylate
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- Novel Compositions for Treating or Preventing Dermal Disorders
- Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- Sirolimus and Familial Adenomatous Polyposis (FAP)
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers
- A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
- Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome
- Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen
- Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
- Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
- Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
- Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
- Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
- Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
- The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
- A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
- Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- 3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
- Omental Islet Transplant
- A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
- The Effect of DPP4 Inhibitor on Vasclular Healing
- HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
- HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
- Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
- Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
- A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
- Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
- UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
- Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
- Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Re
- Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
- To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related Stricture
- Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
- Aging Mammary Stem Cells and Breast Cancer Prevention
- Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care
- Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
- Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
- Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
- Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
- Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
- Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
- Sirolimus for the Treatment of Hyperinsulinism
- Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
- Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
- suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS
- Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
- Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)
- A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
- Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
- COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
- Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
- PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
- The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors
- Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA
- Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
- Safety and Durability of Sirolimus for Treatment of LAM
- Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
- Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
- Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
- Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
- Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
- Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
- Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Comparison of Biomatrix and Orsiro Drug Eluting Stent
- Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition
- Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition
- Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
- Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
- A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAK
- Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease
- Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus
- Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant
- DES Versus BiOSS LIM - POLBOS II Study
- Sirolimus Prophylaxis for aGVHD in TME SCID
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- Haploidentical Hematopoietic Stem Cell Transplantation
- Everolimus for Children With Recurrent or Progressive Ependymoma
- Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
- A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
- Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
- Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
- An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
- Calcineurin Inhibitor Based Immunosuppression Withdrawal
- A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
- Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
- Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
- Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
- Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients
- SRL (Sirolimus) Withdrawal
- Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
- Safety of Simvastatin in LAM and TSC
- Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease
- Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
- SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
- SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
- Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- Comparing Everolimus and Sirolimus in Renal Transplant Recipients
- ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP
- Once-a-day Immunosuppression(CISECON_a_day)
- A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
- Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
- Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
- Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
- Rapalogues for Autism Phenotype in TSC: A Feasibility Study
- In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
- Belatacept Therapy for the Failing Renal Allograft
- Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
- Cardiac Allograft Remodeling and Effects of Sirolimus
- Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery
- Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
- Bortezomib in Late Antibody-mediated Kidney Transplant Rejection
- Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
- Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
- Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
- Non-Myeloablative Conditioning and Bone Marrow Transplantation
- Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
- A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
- Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
- Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
- A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects
- Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients
- Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
- Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
- Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
- Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
- Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone
- Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
- Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
- Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity
- The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
- Islet Allotransplantation in Type 1 Diabetes
- The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
- Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
- Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma
- Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients
- Sirolimus for Massive Polycystic Liver
- Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
- Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
- Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
- Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
- Using mTOR Inhibitors in the Prevention of BK Nephropathy
- The Vienna RAP Pilot Study
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
- Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
- Rapamune Improves Outcomes of Severe H1N1 Pneumonia
- A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
- Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention
- Sirolimus Use in Angioplasty for Vascular Access Extension
- Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient
- Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling
- Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
- Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
- Sirolimus Injections for Autoimmune Scleritis
- Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
- Kidney Allograft Dysfunction Without Reversible Causes
- Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants
- Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients
- Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
- In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease
- Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies
- Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory
- Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- Sirolimus for Advanced Age-Related Macular Degeneration
- Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
- Reduced Intensity Double Umbilical Cord Blood Transplantation
- Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
- Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
- Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)
- Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.
- Extended Follow-Up After Islet Transplantation in T1D
- A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.
- Study Assessing Double-masked Uveitis Treatment
- Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
- Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
- Research Study of ATG and Rituximab in Renal Transplantation
- Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
- Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
- Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
- Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
- Intravitreal Sirolimus as Therapeutic Approach to Uveitis
- Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
- A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
- Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
- Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions
- Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
- Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation
- Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
- Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency
- Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
- Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
- Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.
- Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
- Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
- Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
- A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
- A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
- An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
- Tandem Auto-Allo Transplant for Lymphoma
- Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
- Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
- Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours
- Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
- Lapatinib With Sirolimus or Metformin
- Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
- Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers
- Calcineurin Inhibitor Sparing After Kidney Transplantation
- A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
- Docetaxel and Sirolimus in Patients With Advanced Malignancies
- B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure
- Comparison of Tacrolimus and Myfortic Versus Tacrolimus and Sirolimus
- A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients
- Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
- Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
- Rapamycin and Regulatory T Cells in Kidney Transplantation
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- Sirolimus Conversions in African-American Renal Transplant Recipients
- Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
- Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
- Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
- Doxycycline In Lymphangioleiomyomatosis (LAM)
- Haploidentical PBMC Transplant for Severe Congenital Anemias
- Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
- Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
- Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
- CYPRESS - CYPHER for Evaluating Sustained Safety
- Sirolimus and Cetuximab in Advanced Malignancies
- Polycystic Liver Disease in Kidney Transplant
- Tacrolimus to Sirolimus Conversion for Delayed Graft Function
- Topical Rapamycin for Fibrofolliculomas
- Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
- Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
- Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC
- Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
- Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
- Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
- Sirolimus as Therapeutic Approach to Uveitis
- Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
- Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
- Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
- Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti
- Rapamycin in Relapsed Acute Lymphoblastic Leukemia
- Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
- Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
- Oral Sirolimus for In-Stent Restenosis
- A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study
- Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
- A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
- Calcineurin Free Immunosuppression in Renal Transplant Recipients
- Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation
- Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
- CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
- Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation
- A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
- Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
- Prospective Study of Rapamycin for the Treatment of SLE
- Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
- Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
- Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
- Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
- A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
- Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
- Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
- Sirolimus to Treat Diabetic Macular Edema
- Study of Rapamycin Plus Ketoconazole in Advanced Cancers
- Rapamycin in Advanced Cancers
- Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
- Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
- Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing
- Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
- A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
- Tacrolimus/Sirolimus Versus Tacrolimus/Mycophenolate Mofetil (MMF) Versus Neoral/Sirolimus in Adult, Primary Kidney Transplantation
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
- Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
- A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
- Rapamycin Plus Bevacizumab in Advanced Cancers
- Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
- A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
- Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Rapamycin for Prevention of Chronic Graft-Versus-Host Disease
- Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
- Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
- CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
- Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation
- Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent
- Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
- Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
- Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
- Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
- Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression
- Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
- Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
- TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic
- Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
- Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
- Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction
- Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
- Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment
- Proleukin and Rapamune in Type 1 Diabetes
- Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
- Study Comparing Standard Dose and Reduced Dose Tacrolimus With Sirolimus in Renal Transplant Patients
- Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus
- Study Comparing Standard Dose and Reduced Dose Tacrolimus + Sirolimus + Corticosteroids in Renal Allograft Recipients
- Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
- Phase 1 Study With Sorafenib and Sirolimus
- Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
- Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus
- Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
- Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
- Sirolimus in Treating Patients With Advanced Pancreatic Cancer
- Fibrosis in Renal Allografts
- Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety
- Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
- Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
- Study Investigating Rapamune For Post-Marketing Surveillance
- Comparison Between Pioglitazone and SES With type2 DM
- Study Evaluating Rapamune® Maintenance Regimen
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
- Study Comparing Sirolimus/Prograf vs Sirolimus/CsA in High-Risk Renal Transplant Recipients
- B-Lymphocyte Immunotherapy in Islet Transplantation
- Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant
- Strategies to Improve Islet Survival
- Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
- A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
- Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient
- Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
- Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
- Islet Transplantation in Type 1 Diabetes
- Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
- Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients
- Donor Stem Cell Transplantation for Congenital Immunodeficiencies
- Anti-Restenosis After AMI by Erythropoietin
- Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
- A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
- Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
- Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts
- The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
- Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
- Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
- Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
- Sirolimus for Autoimmune Disease of Blood Cells
- Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease
- Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
- PIoglitazone for PrEvention of Restenosis in Diabetic Patients
- Rapamycin With Grapefruit Juice for Advanced Malignancies
- Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts
- Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
- Sirolimus in Treating Patients With Metastatic or Unresectable Solid Tumors
- "A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
- Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Nonca
- Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
- Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
- Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
- TBI Dose De-escalation for Fanconi Anemia
- Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
- Pilot Study for HLA Identical Living Donor Renal Transplant Recipients
- Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
- Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
- A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
- De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
- Comparison of Sirolimus and Azathioprine in Lung Transplantation
- Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
- Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
- Simultaneous Pancreas-kidney Transplantation With Campath Protocol
- Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
- Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
- Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
- Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
- Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
- Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
- Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression
- Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
- Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
- Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration
- To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.
- hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients
- Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
- Study Evaluating Sirolimus in the Treatment of Kidney Transplant
- Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
- Islet Transplantation Using Abatacept
- The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
- The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
- Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
- Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
- Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
- Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients
- Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus
- Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Study Evaluating Rapamune in Patients After Kidney Transplantation
- Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients
- MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
- Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
- Polymorphism of the Cytochrome P450-system in Renal Transplants
- Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation
- Islet Transplantation in Type 1 Diabetic Patients
- Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients
- Study Evaluating Sirolimus in Kidney Transplant Recipients in India
- Study Comparing Cyclosporine Dose Reduction vs. Cyclosporine Elimination in Kidney Transplant Recipients Taking Sirolimus
- A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients
- Study Evaluating Sirolimus in Kidney Transplant Recipients
- Study Evaluating Rapamune in Transplant Recipients in the Nordic Countries
- Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans
- Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant
- Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
- Islet Transplantation Using Campath-1H and Infliximab Induction
- Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
- Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
- Study Evaluating Sirolimus in Kidney Transplant Recipients.
- Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment
- Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
- The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus
- The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients
- A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
- Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
- Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
- Efficacy and Safety of Sirolimus in Combination With Tacrolimus
- European Trial of Immunosuppression in SPK Tx
- Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
- Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
- Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
- Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
- Sirolimus in Treating Patients With Angiomyolipoma of the Kidney
- Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
- Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
- Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
- Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
- Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients
- Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment
- Daclizumab and Sirolimus to Treat Uveitis
- Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
- Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
- Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
- Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients
- Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
- Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
- Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
- Sirolimus in Treating Patients With Glioblastoma Multiforme
- Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
- Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
- Sirolimus for Focal Segmental Glomerulosclerosis
- Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
- Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
- Blood and Marrow Transplant Clinical Research Network
- Steroid Withdrawal in Pediatric Kidney Transplant Recipients
- Pediatric Kidney Transplant Without Calcineurin Inhibitors
- Islet Transplantation for Type 1 Diabetes
- Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
- A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant
- Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
- Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Clinical trials list
click for details